Recombinant Human TR11B Protein (Active) is a Human Fragment protein, in the 22 to 401 aa range, expressed in HEK 293, <= 0.005 EU/µg endotoxin level and suitable for SDS-PAGE, FuncS, MS.
Images
Key facts
- Purity
- HPLC
- Endotoxin level
- <= 0.005 EU/µg
- Expression system
- HEK 293 cells
- Tags
- Tag free
- Applications
- SDS-PAGE, FuncS, MS
- Biologically active
- Yes
Amino acid sequence
E T F P P K Y L H Y D E E T S H Q L L C D K C P P G T Y L K Q H C T A K W K T V C A P C P D H Y Y T D S W H T S D E C L Y C S P V C K E L Q Y V K Q E C N R T H N R V C E C K E G R Y L E I E F C L K H R S C P P G F G V V Q A G T P E R N T V C K R C P D G F F S N E T S S K A P C R K H T N C S V F G L L L T Q K G N A T H D N I C S G N S E S T Q K C G I D V T L C E E A F F R F A V P T K F T P N W L S V L V D N L P G T K V N A E S V E R I K R Q H S S Q E Q T F Q L L K L W K H Q N K D Q D I V K K I I Q D I D L C E N S V Q R H I G H A N L T F E Q L R S L M E S L P G K K V G A E D I E K T I K A C K P S D Q I L K L L S L W R I K N G D Q D T L K G L M H A L K H S K T Y H F P K T V T Q S L K K T I R F L H S F T M Y K L Y Q K L F L E M I G N Q V Q S V K I S C L
Reactivity data
| Application | Reactivity | Dilution info | Notes |
|---|---|---|---|
Application SDS-PAGE | Reactivity Reacts | Dilution info - | Notes - |
Application FuncS | Reactivity Reacts | Dilution info - | Notes - |
Application MS | Reactivity Reacts | Dilution info - | Notes - |
Target data
Function
Acts as a decoy receptor for TNFSF11/RANKL and thereby neutralizes its function in osteoclastogenesis. Inhibits the activation of osteoclasts and promotes osteoclast apoptosis in vitro. Bone homeostasis seems to depend on the local ratio between TNFSF11 and TNFRSF11B. May also play a role in preventing arterial calcification. May act as decoy receptor for TNFSF10/TRAIL and protect against apoptosis. TNFSF10/TRAIL binding blocks the inhibition of osteoclastogenesis.
Alternative names
OCIF, OPG, TNFRSF11B, Tumor necrosis factor receptor superfamily member 11B, Osteoclastogenesis inhibitory factor, Osteoprotegerin
Recommended products
Recombinant Human TR11B Protein (Active) is a Human Fragment protein, in the 22 to 401 aa range, expressed in HEK 293, <= 0.005 EU/µg endotoxin level and suitable for SDS-PAGE, FuncS, MS.
Key facts
- Purity
- HPLC
- Endotoxin level
- <= 0.005 EU/µg
- Expression system
- HEK 293 cells
- Tags
- Tag free
- Applications
- SDS-PAGE, FuncS, MS
- Biologically active
- Yes
- Biological activity
Fully biologically active determined by dose-dependent inhibition of RANKL-mediated NF-kb activation in mouse RAW264.7 NF-kb luciferase reporter cell line.
ED50 is ≤ 56.66, corresponding to a specific activity of 1.8 X 104 units/mg.
- Accession
- O00300-1
- Animal free
- Yes
- Species
- Human
- Reconstitution
- Reconstitute in PBS
- Concentration
- Storage buffer
pH: 7.4
Constituents: 10.26% Trehalose, 0.727% Dibasic monohydrogen potassium phosphate, 0.248% Potassium phosphate monobasic
Sequence info
Amino acid sequence
- E T F P P K Y L H Y D E E T S H Q L L C D K C P P G T Y L K Q H C T A K W K T V C A P C P D H Y Y T D S W H T S D E C L Y C S P V C K E L Q Y V K Q E C N R T H N R V C E C K E G R Y L E I E F C L K H R S C P P G F G V V Q A G T P E R N T V C K R C P D G F F S N E T S S K A P C R K H T N C S V F G L L L T Q K G N A T H D N I C S G N S E S T Q K C G I D V T L C E E A F F R F A V P T K F T P N W L S V L V D N L P G T K V N A E S V E R I K R Q H S S Q E Q T F Q L L K L W K H Q N K D Q D I V K K I I Q D I D L C E N S V Q R H I G H A N L T F E Q L R S L M E S L P G K K V G A E D I E K T I K A C K P S D Q I L K L L S L W R I K N G D Q D T L K G L M H A L K H S K T Y H F P K T V T Q S L K K T I R F L H S F T M Y K L Y Q K L F L E M I G N Q V Q S V K I S C L
- Accession
- O00300
- Protein length
- Fragment
- Predicted molecular weight
- 43.67 kDa
- Actual molecular weight
- 43.68 kDa
- Amino acids
- 22 to 401
- Nature
- Recombinant
Specifications
- Form
- Lyophilized
General info
- Function
Acts as a decoy receptor for TNFSF11/RANKL and thereby neutralizes its function in osteoclastogenesis. Inhibits the activation of osteoclasts and promotes osteoclast apoptosis in vitro. Bone homeostasis seems to depend on the local ratio between TNFSF11 and TNFRSF11B. May also play a role in preventing arterial calcification. May act as decoy receptor for TNFSF10/TRAIL and protect against apoptosis. TNFSF10/TRAIL binding blocks the inhibition of osteoclastogenesis.
- Post-translational modifications
N-glycosylated. Contains sialic acid residues.
Storage
- Shipped at conditions
- Ambient - Can Ship with Ice
- Appropriate short-term storage conditions
- Ambient
- Appropriate long-term storage conditions
- Ambient
This product is an active protein and may elicit a biological response in vivo, handle with caution.
Supplementary info
- This supplementary information is collated from multiple sources and compiled automatically.
- Activity summary
Osteoprotegerin (OPG) also known as osteoclastogenesis inhibitory factor is a glycoprotein with a mass of approximately 60 kDa. It acts as a soluble decoy receptor for receptor activator of nuclear factor kappa-Β ligand (RANKL) and is encoded by the TNFRSF11B gene. OPG is mainly expressed in osteoblasts fibroblasts and endothelial cells. Its expression can be found in diverse tissues throughout the body including the liver and lungs.
- Biological function summary
OPG inhibits the differentiation and activation of osteoclasts by binding to RANKL preventing its interaction with the receptor RANK on the surface of osteoclast progenitor cells. As part of a non-classical signaling pathway OPG plays a significant role in the regulation of bone remodeling and maintenance by controlling bone resorption. This activity preserves bone density and structure by limiting excessive osteoclastic activity.
- Pathways
OPG operates within the RANK/RANKL/OPG signaling axis which is important for bone metabolism. It counteracts the bone-resorption pathway driven by the RANKL-RANK interaction inhibiting osteoclastogenesis. This axis involves interactions with other proteins such as RANK RANKL and TRAIL where TRAIL’s involvement hints towards a broader immune regulation role for OPG.
- Associated diseases and disorders
OPG has a significant association with conditions such as osteoporosis and vascular calcification. In osteoporosis an imbalance in the RANKL/OPG ratio can lead to excessive bone loss due to increased osteoclast activity. In vascular calcification OPG appears to play a protective role likely linked with regulatory mechanisms involving RANKL and TRAIL. Understanding these interactions opens potential therapeutic avenues particularly in managing bone-related and cardiovascular conditions.
Product promise
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
2 product images
Mass Spectrometry - Recombinant Human TR11B Protein (Active) (ab287918)
Mass determination by ESI-TOF. Predicted MW is 43674 Da (+/-10 Da by ESI-TOF). Observed MW is 43679.71 Da.
Functional Studies - Recombinant Human TR11B Protein (Active) (ab287918)
Fully biologically active determined by dose-dependent inhibition of RANKL-mediated NF-kb activation in mouse RAW264.7 NF-kb luciferase reporter cell line.
ED50 is ≤ 56.66, corresponding to a specific activity of 1.8 X 10⁴ units/mg.
Cell based assay testing is performed on the first lot of protein only and is provided as a reference for protein activity; subsequent lots of protein must pass all biophysical quality control parameters that meet the same parameters as the first lot. Lot GR3432994-1.
Downloads
Product protocols
- Visit the general protocols
- Visit troubleshooting
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com